Delivery Order SPE2DB22D2211-SPE2DB25FRZPG

Award Date 6/24/25
Potential Completion Date 6/25/25
Potential Value $2.1K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of Ondansetron ODT 8 mg tablets, with a ceiling value of $1,833.54 and a period of performance through June 17, 2025. The contract is not set aside and represents an open competition. AmerisourceBergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of Ondansetron ODT 4 mg tablets. The $3,361.80 contract has a June 26, 2025 completion date and is not designated as a set-aside. AmerisourceBergen holds a significant $999,999,999.00 Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, which serves as a comprehensive global pharmaceutical support vehicle for...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $2,536.12, is for the delivery of 4,568,235,550 units of Ondansetron ODT 8 mg tablets in a 30-count package. The award has an ultimate completion date of May 14, 2025. Amerisourcebergen Drug Corp is the prime contractor, and the contract is not set aside for any particular...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of Ondansetron ODT 4 mg tablets. The contract is a firm fixed-price, non-set-aside arrangement with a ceiling value of $10,788.00 and a period of performance through May 2, 2025. AmerisourceBergen Drug Corp holds a larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00, which provides a comprehensive...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of Ondansetron ODT 8 mg tablets. The $1,295.75 firm fixed-price contract has a period of performance through May 16, 2024 and does not utilize any set-aside requirements. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical to provide a wide range of pharmaceutical products and medical...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the supply of Ondansetron ODT 4 mg tablets. The contract has a ceiling value of $1,464.48 and a performance period extending through June 13, 2025. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999.00, which serves as a comprehensive...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the supply of Ondansetron ODT 8 mg tablets. The $2,768.58 contract has an ultimate completion date of September 11, 2024. No set-aside designation was used. Amerisourcebergen holds a larger Indefinite Delivery Contract with DLA Troop Support Medical, valued at up to $999,999,999 through December 2025, for delivering a wide range of...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of Ondansetron ODT 8 mg tablets in 30-count packages, with a total ceiling value of $14,406.77 and a period of performance through February 12, 2025. This delivery order is part of a larger Indefinite Delivery Contract (IDC) held by Amerisourcebergen with the DLA Troop Support Medical, valued at...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the supply of Ondansetron ODT 4 mg tablets. The contract has a ceiling value of $1,978.45 and a period of performance ending on May 13, 2025. It is not designated as a set-aside contract, indicating open competition. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $12,839.76, is for the delivery of Ondansetron HCL 8 mg tablets. The contract has an ultimate completion date of June 10, 2025 and is not set aside. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at...
  • SPE2DB22D2211
    Indefinite Delivery Contract
  • SPE2DB22D2211-SPE2DB25FRZPG
    Delivery Order

This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $2,111.31 contract is for the delivery of Ondansetron ODT 8 mg tablets, with a period of performance through June 25, 2025.

Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999.00, which provides a comprehensive global pharmaceutical support vehicle through December 2026. This IDC enables the company to supply a wide range of pharmaceutical products and medical supplies to support military healthcare programs worldwide, serving customers including the Defense Health Agency and U.S. Coast Guard. The contract award is not designated as a set-aside.

Generated 9/28/25, 1:56 AM